clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2024-102-9-10-727-735clinmed-949Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESПрофилактическая гепаринотерапия в акушерской практикеPreventive heparin therapy in obstetric practicehttps://orcid.org/0000-0002-7426-9040МельниковА. П.MelnikovA. P.

 Мельников Андрей Павлович — канд. мед. наук, старший научный сотрудник

Москва

Andrey P. Melnikov — Candidate of Medical Sciences, Senior Researcher

Moscow

https://orcid.org/0009-0007-1560-5642ХрусталеваТ. Ю.KhrustalevaT. Yu.

Хрусталева Таисия Юрьевна, клинический ординатор

Москва

Taisiua Yu. Khrustaleva — clinical resident

Moscow

khrustalev100@mail.ruhttps://orcid.org/0000-0001-5331-2655БокаревИ. Н.BokarevI. N.

Бокарев Игорь Николаевич — д-р мед. наук, профессор, президент

Москва

Igor N. Bokarev — Doctor of Medical Sciences, Professor, President 

Moscow

ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии им. акад. В.И. Краснопольского»; Всероссийская Ассоциация по изучению тромбозов, геморрагий, патологии сосудов им. А.А. Шмидта–Б.А. КудряшоваРоссияMoscow Regional Research Institute of Obstetrics and Gynecology named after V.I. Krasnopolsky; Russian Association on Thrombosis, Hemostasis and Vascular Pathology named after A. Schmidt–B. KudryashovRussian FederationГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии им. акад. В.И. Краснопольского»РоссияMoscow Regional Research Institute of Obstetrics and Gynecology named after V.I. KrasnopolskyRussian FederationВсероссийская Ассоциация по изучению тромбозов, геморрагий, патологии сосудов им. А.А. Шмидта–Б.А. КудряшоваРоссияRussian Association on Thrombosis, Hemostasis and Vascular Pathology named after A. Schmidt–B. KudryashovRussian Federation2024050220251029-10727–735Copyright © Мельников А.П., Хрусталева Т.Ю., Бокарев И.Н., 20252025Мельников А.П., Хрусталева Т.Ю., Бокарев И.Н.Melnikov A.P., Khrustaleva T.Y., Bokarev I.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/949

В акушерской практике большое число пациенток получают антикоагулянтные препараты с профилактической целью. Представлен обзор используемых гепаринов; рассмотрены клинические ситуации, когда проводятся профилактическое лечение гепаринами, включая вспомогательные репродуктивные технологии, акушерские осложнения беременности, особенности родоразрешения, тромботические осложнения, экстрагенитальная патология. Обсуждаются возможности улучшения исходов профилактического лечения гепаринами и предупреждения возникающих осложнений.

In obstetric practice, a significant number of patients receive anticoagulant medications for prophylactic purposes. This review presents the types of heparins used and examines clinical situations where prophylactic treatment with heparins is administered, including assisted reproductive technologies, obstetric complications of pregnancy, aspects of delivery, thrombotic complications, and extragenital pathology. The possibilities for improving the outcomes of prophylactic treatment with heparins and preventing arising complications are discussed.

гепаринотерапия при беременностиакушерские осложненияэкстрагенитальная патологияпрофилактика тромбозовheparin therapy during pregnancyobstetric complicationsextragenital pathologythrombosis preventionReferencesСловарь иностранных слов. Издание 8, стереотипное. Стр. 416. Москва: "Русский язык", 1981.Dictionary of Foreign Words. Edition 8 stereotype. Pp. 416. “Russian language”. Moscow, 1981 (In Russian)].Pastori D., Cormaci V.M., Marucci S., Franchino G., Del Sole F., Capozza A.et al. A Comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology. Int. J. Mol. Sci. 2023;24(4):31–69. DOI: 10.3390/ijms24043169Pastori D., Cormaci V.M., Marucci S., Franchino G., Del Sole F., Capozza A.et al. A Comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology. Int. J. Mol. Sci. 2023;24(4):31–69. DOI: 10.3390/ijms24043169Bates S.M., Rajasekhar A., Middeldorp S., McLintock C., Rodger M.A., James A.H.et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2(22):3317–3359. DOI: 10.1182/bloodadvances.2018024802Bates S.M., Rajasekhar A., Middeldorp S., McLintock C., Rodger M.A., James A.H.et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2(22):3317–3359. DOI: 10.1182/bloodadvances.2018024802Eke A.C. An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics. J. Basic Clin. Physiol. Pharmacol. 2022;33(5):581–598. DOI: 10.1515/jbcpp-2021-0312Eke A.C. An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics. J. Basic Clin. Physiol. Pharmacol. 2022;33(5):581–598. DOI: 10.1515/jbcpp-2021-0312Pariente G., Leibson T., Carls A., Adams-Webber T., Ito S., Koren G. Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. PLoS Med. 2016;13(11): e1002160. eCollection 2016 Nov. DOI: 10.1371/journal.pmed.1002160Pariente G., Leibson T., Carls A., Adams-Webber T., Ito S., Koren G. Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. PLoS Med. 2016;13(11): e1002160. eCollection 2016 Nov. DOI: 10.1371/journal.pmed.1002160Abildgaard A., Madsen S.A., Hvas A.-M. Dosage of anticoagulants in obesity: recommendations based on a systematic review. Semin. Thromb. Hemost. 2020;46(8):932–969. DOI: 10.1055/s-0040-1718405Abildgaard A., Madsen S.A., Hvas A.-M. Dosage of anticoagulants in obesity: recommendations based on a systematic review. Semin. Thromb. Hemost. 2020;46(8):932–969. DOI: 10.1055/s-0040-1718405Sultan A.A., West J., Tata L.J, Fleming K.M, Nelson-Piercy C., Grainge M. J. Risk of fi rst venous thromboembolism in and around pregnancy: a population-based cohort study. Br. J. Haematol. 2012;156(3):366–73. DOI: 10.1111/j.1365-2141.2011.08956.xSultan A.A., West J., Tata L.J, Fleming K.M, Nelson-Piercy C., Grainge M. J. Risk of fi rst venous thromboembolism in and around pregnancy: a population-based cohort study. Br. J. Haematol. 2012;156(3):366–73. DOI: 10.1111/j.1365-2141.2011.08956.xSucker C. Prophylaxis and therapy of venous thrombotic events (VTE) in pregnancy and the postpartum period. Geburtshilfe Frauenheilkd. 2020. PMID: 31949319Sucker C. Prophylaxis and therapy of venous thrombotic events (VTE) in pregnancy and the postpartum period. Geburtshilfe Frauenheilkd. 2020. PMID: 31949319Bauersachs R.M., Dudenhausen J., Faridi A., Fischer T., Fung S., Geisen U.et al. Risk stratifi cation and heparin prophylaxis to prevent venous thromboembolism in pregnant women. J. Thromb. Haemost. 2007;98(6):1237–45. DOI: 10.1160/th07-05-0329Bauersachs R.M., Dudenhausen J., Faridi A., Fischer T., Fung S., Geisen U.et al. Risk stratifi cation and heparin prophylaxis to prevent venous thromboembolism in pregnant women. J. Thromb. Haemost. 2007;98(6):1237–45. DOI: 10.1160/th07-05-0329Nicholson M.J., Chan N., Bhagirath V., Ginsberg J. Prevention of venous thromboembolism in 2020 and beyond. J. Clin. Med. 2020;9(8):2467. DOI: 10.3390/jcm9082467Nicholson M.J., Chan N., Bhagirath V., Ginsberg J. Prevention of venous thromboembolism in 2020 and beyond. J. Clin. Med. 2020;9(8):2467. DOI: 10.3390/jcm9082467Шабанова Н.А., Зайнулина М.С. Современные подходы к профи лактике тромбоэмболических осложнений при беременности. Журнал акушерства и женских болезней. 2011;LX(3):161–168.Shabanova N.A., Zainulina M.S. Modern approaches to the prevention of thromboembolic complications in pregnancy. Journal of Obstetrics and Women’s Diseases, 2011;LX(3):161–168. (In Russian)].Zakai N A, McClure L A. Racial diff erences in venous thromboembolism. J. Thromb. Haemost. 2011;9(10):1877–82. DOI: 10.1111/j.1538-7836.2011.04443.xZakai N A, McClure L A. Racial diff erences in venous thromboembolism. J. Thromb. Haemost. 2011;9(10):1877–82. DOI: 10.1111/j.1538-7836.2011.04443.xNakayama T., Mitsuno R., Torimitsu T., Yoshimoto N., Kanda T., Tokuyama H.et al. Diffi culty in managing nephrotic syndrome-associated cerebral venous thrombosis. CEN Case Rep. 2021;10(1):132–138. DOI: 10.1007/s13730-020-00520-7Nakayama T., Mitsuno R., Torimitsu T., Yoshimoto N., Kanda T., Tokuyama H.et al. Diffi culty in managing nephrotic syndrome-associated cerebral venous thrombosis. CEN Case Rep. 2021;10(1):132–138. DOI: 10.1007/s13730-020-00520-7Мельников А.П., Кащук М.Г., Ахвледиани К.Н., Бокарев И.Н. Тромбофилия в акушерской практике. Клиническая медицина. 2021; 99(1): 15-20.Melnikov A.P., Kashchuk M.G., Akhvlediani K.N., Bokarev I.N. Thrombophilia in obstetric practice. Clinicheskya Medicina 2021;99(1):15–20. (In Russian)].Arachchillage D.J., Mackillop L., Chandratheva A., Motawani J., MacCallum P., Laff an M. Thrombophilia testing: A British Society for Haematology guideline. Br. J. Haematol. 2022;198(3):443–458. DOI: 10.1111/bjh.18239Arachchillage D.J., Mackillop L., Chandratheva A., Motawani J., MacCallum P., Laff an M. Thrombophilia testing: A British Society for Haematology guideline. Br. J. Haematol. 2022;198(3):443–458. DOI: 10.1111/bjh.18239Folkeringa N., Brouwer J.L.P., Korteweg F. J., Veeger N.J.G.M., Erwich J.J.H.M., Holm J. P., van der Meer J. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S defi cient women. Clinical Trial Br. J. Haematol. 2007;136(4):656–61. DOI: 10.1111/j.1365-2141.2006.06480.xFolkeringa N., Brouwer J.L.P., Korteweg F. J., Veeger N.J.G.M., Erwich J.J.H.M., Holm J. P., van der Meer J. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S defi cient women. Clinical Trial Br. J. Haematol. 2007;136(4):656–61. DOI: 10.1111/j.1365-2141.2006.06480.xMukhopadhyay S., Johnson T.A., Duru N., Buzza M.S., Pawar N.R., Sarkar R., Antalis T.M. Fibrinolysis and infl ammation in venous thrombus resolution. Front. Immunol. 2019;10:1348. DOI: 10.3389/fimmu.2019.01348Mukhopadhyay S., Johnson T.A., Duru N., Buzza M.S., Pawar N.R., Sarkar R., Antalis T.M. Fibrinolysis and infl ammation in venous thrombus resolution. Front. Immunol. 2019;10:1348. DOI: 10.3389/fimmu.2019.01348Huang Y., Li F., Li C., Liao X. Effi cacy of low molecular weight heparin in preventing perinatal venous thrombosis: a meta-analysis. Comput. Math. Methods Med. 2022;2022:1248577. DOI: 10.1155/2022/1248577Huang Y., Li F., Li C., Liao X. Effi cacy of low molecular weight heparin in preventing perinatal venous thrombosis: a meta-analysis. Comput. Math. Methods Med. 2022;2022:1248577. DOI: 10.1155/2022/1248577Wiegers H.M.G., Middeldorp S. Contemporary best practice in the management of pulmonary embolism during pregnancy. Ther. Adv. Respir. Dis. 2020;14:1753466620914222. DOI: 10.1177/1753466620914222Wiegers H.M.G., Middeldorp S. Contemporary best practice in the management of pulmonary embolism during pregnancy. Ther. Adv. Respir. Dis. 2020;14:1753466620914222. DOI: 10.1177/1753466620914222Wiegers H.M. G., Farkas D. K., Horváth-Puhó E., Middeldorp S., van Es N., Sørensen H. T. Incidence and prognosis of superfi cial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study. The Lancet Haematology. 2023;10(5):e359– e366. DOI: 10.1016/S2352-3026(23)00013-3.Wiegers H.M. G., Farkas D. K., Horváth-Puhó E., Middeldorp S., van Es N., Sørensen H. T. Incidence and prognosis of superfi cial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study. The Lancet Haematology. 2023;10(5):e359– e366. DOI: 10.1016/S2352-3026(23)00013-3.Notten P., van Laanen J.H.H., Eijgenraam P., de Wolf M.A.F., Kurstjens R.L.M., ten Cate H., ten Cate‐Hoek A. Quality of anticoagulant therapy and the incidence of in‐stent thrombosis after venous stenting. J. Res. Pract. Thromb. Haemost. 2020;4(4):594–603. DOI: 10.1002/rth2.12330Notten P., van Laanen J.H.H., Eijgenraam P., de Wolf M.A.F., Kurstjens R.L.M., ten Cate H., ten Cate‐Hoek A. Quality of anticoagulant therapy and the incidence of in‐stent thrombosis after venous stenting. J. Res. Pract. Thromb. Haemost. 2020;4(4):594–603. DOI: 10.1002/rth2.12330Bistervels I.M., Geerlings A. E., Bonta P. ., Ganzevoort W., Zijlstra I.J.A.J., Middeldorp S. Pregnancy in women with an inferior vena cava fi lter: a tertiary center experience and overview of the literature. Blood Adv. 2021;5(20):4044–4053. DOI: 10.1182/bloodadvances.2020003930Bistervels I.M., Geerlings A. E., Bonta P. ., Ganzevoort W., Zijlstra I.J.A.J., Middeldorp S. Pregnancy in women with an inferior vena cava fi lter: a tertiary center experience and overview of the literature. Blood Adv. 2021;5(20):4044–4053. DOI: 10.1182/bloodadvances.2020003930Manasanch E.E., Lozier G.N. Venous thromboembolism. pp.338–355 in The Bethesda Handbook of Clinical Hematology. (4 ed.) Editors: G.P. Rodgers, N.S. Young. Wolters Kluver. 2018.Manasanch E.E., Lozier G.N. Venous thromboembolism. pp.338–355 in The Bethesda Handbook of Clinical Hematology. (4 ed.) Editors: G.P. Rodgers, N.S. Young. Wolters Kluver. 2018.Bianca I., Geraci G., Gulizia M.M., Assenza G.E., Barone C., Campisi M.et al. Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Pediatric Cardiology (SICP), and Italian Society of Gynaecologists and Obstetrics (SIGO): pregnancy and congenital heart diseases. Eur. Heart J. Suppl. 2017;19(D):D256–D292. DOI: 10.1093/eurheartj/sux032Bianca I., Geraci G., Gulizia M.M., Assenza G.E., Barone C., Campisi M.et al. Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Pediatric Cardiology (SICP), and Italian Society of Gynaecologists and Obstetrics (SIGO): pregnancy and congenital heart diseases. Eur. Heart J. Suppl. 2017;19(D):D256–D292. DOI: 10.1093/eurheartj/sux032Shu L., Bakradze E., Omran S.S., Giles J., Amar J., Henninger N.et al. Predictors of recurrent venous thrombosis after cerebral venous thrombosis. Neurology. 2022;99(21):e2368–e2377. DOI: 10.1212/WNL.0000000000201122Shu L., Bakradze E., Omran S.S., Giles J., Amar J., Henninger N.et al. Predictors of recurrent venous thrombosis after cerebral venous thrombosis. Neurology. 2022;99(21):e2368–e2377. DOI: 10.1212/WNL.0000000000201122Roeder H.J., Lopez J. R., Miller E.C. Ischemic stroke and cerebral venous sinus thrombosis in pregnancy. Handb. Clin. Neurol. 2020;172:3–31.DOI: 10.1016/B978-0-444-64240-0.00001-5Roeder H.J., Lopez J. R., Miller E.C. Ischemic stroke and cerebral venous sinus thrombosis in pregnancy. Handb. Clin. Neurol. 2020;172:3–31.DOI: 10.1016/B978-0-444-64240-0.00001-5Sharma N., Sharma S.R., Hussain M. An audit of cerebral venous thrombosis associated with pregnancy and puerperium in teaching hospital in North Eastern India. J. Family Med. Prim. Care. 2019;8(3):1054–1057.DOI: 10.4103/jfmpc.jfmpc_366_18Sharma N., Sharma S.R., Hussain M. An audit of cerebral venous thrombosis associated with pregnancy and puerperium in teaching hospital in North Eastern India. J. Family Med. Prim. Care. 2019;8(3):1054–1057.DOI: 10.4103/jfmpc.jfmpc_366_18Meng S.-H., Li J-H., Zuo L-J., Feng L.-M. The outcomes of pregnant and postpartum patients with cerebral venous sinus thrombosis after anticoagulant therapy. Monitoring editor: Baradwan S.M. Medicine (Baltimore). 2021;100(26):e26360. DOI: 10.1097/MD.0000000000026360Meng S.-H., Li J-H., Zuo L-J., Feng L.-M. The outcomes of pregnant and postpartum patients with cerebral venous sinus thrombosis after anticoagulant therapy. Monitoring editor: Baradwan S.M. Medicine (Baltimore). 2021;100(26):e26360. DOI: 10.1097/MD.0000000000026360Hamulyák E.N., Scheres L. J.J, Marijnen M.C., Goddijn M., Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst. Rev. 2020;2020(5):CD012852. DOI: 10.1002/14651858.CD012852.pub2Hamulyák E.N., Scheres L. J.J, Marijnen M.C., Goddijn M., Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst. Rev. 2020;2020(5):CD012852. DOI: 10.1002/14651858.CD012852.pub2Bala M.M., Paszek E., Lesniak W., Wloch-Kopec D., Jasinska K., Undas A. Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. Cochrane Database Syst. Rev. 2018;7(7):CD012534. DOI: 10.1002/14651858.CD012534.pub2Bala M.M., Paszek E., Lesniak W., Wloch-Kopec D., Jasinska K., Undas A. Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. Cochrane Database Syst. Rev. 2018;7(7):CD012534. DOI: 10.1002/14651858.CD012534.pub2Bates S.M., Greer I.A., Middeldorp S., Veenstra D.L., Prabulos A.-M., Vandvik P. O. VTE, thrombophilia, antithrombotic therapy, and pregnancy . Chest. 2012;141(2):e691S–e736S. DOI: 10.1378/chest.11-2300Bates S.M., Greer I.A., Middeldorp S., Veenstra D.L., Prabulos A.-M., Vandvik P. O. VTE, thrombophilia, antithrombotic therapy, and pregnancy . Chest. 2012;141(2):e691S–e736S. DOI: 10.1378/chest.11-2300Chaturvedi S., Braunstein E. M., Brodsky R.A. Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications. J. Thromb. Haemost. 2021;19(3):607–616. DOI: 10.1111/jth.15082Chaturvedi S., Braunstein E. M., Brodsky R.A. Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications. J. Thromb. Haemost. 2021;19(3):607–616. DOI: 10.1111/jth.15082Antic D., Lefkou E., Otasevic V., Banfi c L., Dimakakos E., Oli nic D. et al. Position paper on the management of pregnancy-associated superfi cial venous thrombosis. Clin. Appl. Thromb. Hemost. 2022;28:1076029620939181. DOI: 10.1177/1076029620939181Antic D., Lefkou E., Otasevic V., Banfi c L., Dimakakos E., Oli nic D. et al. Position paper on the management of pregnancy-associated superfi cial venous thrombosis. Clin. Appl. Thromb. Hemost. 2022;28:1076029620939181. DOI: 10.1177/1076029620939181Malhamé I., Othman M., Casais P., D’Souza R., Wald R. M., Silversides C. K., Sermer M., Shehata N.Communication from the ISTH SSC Subcommittee on Women’s Health Issues in Thrombosis and Haemostasis: A Survey on Anticoagulation for Mechanical Heart Valves in Pregnancy. J. Thromb. Haemost. 2021;19:859–864. DOI: 10.1111/jth.15213.Malhamé I., Othman M., Casais P., D’Souza R., Wald R. M., Silversides C. K., Sermer M., Shehata N.Communication from the ISTH SSC Subcommittee on Women’s Health Issues in Thrombosis and Haemostasis: A Survey on Anticoagulation for Mechanical Heart Valves in Pregnancy. J. Thromb. Haemost. 2021;19:859–864. DOI: 10.1111/jth.15213.Kariv S., Azibani F., Baard J., Sliwa K., Osman A., Anthony J., Soma-Pillay P. Cardiovasc J. Haemorrhage and other complications in pregnant women on anticoagulation for mechanical heart valves: a prospective observational cohort study. Afr. 2018;29(5):289–295. DOI: 1 0.5830/CVJA-2018-029Kariv S., Azibani F., Baard J., Sliwa K., Osman A., Anthony J., Soma-Pillay P. Cardiovasc J. Haemorrhage and other complications in pregnant women on anticoagulation for mechanical heart valves: a prospective observational cohort study. Afr. 2018;29(5):289–295. DOI: 1 0.5830/CVJA-2018-029Origa R., Comitini F. Mediterr J. Pregnancy in thalassemia. Hematol. Infect. Dis. 2019,11(1):e2019019, DOI: 10.4084/MJHID.2019.019Origa R., Comitini F. Mediterr J. Pregnancy in thalassemia. Hematol. Infect. Dis. 2019,11(1):e2019019, DOI: 10.4084/MJHID.2019.019Geddings J. E., Mackman N. Recently identifi ed factors that regulate hemostasis and thrombosis. Thromb. Haemost. 2014;111(4):570–574. DOI:10.1160/TH13-10-0812Geddings J. E., Mackman N. Recently identifi ed factors that regulate hemostasis and thrombosis. Thromb. Haemost. 2014;111(4):570–574. DOI:10.1160/TH13-10-0812Chiodelli P., Bugatti A., Urbinati C., Rusnati M. Heparin/heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use. Molecules. 2015;20(4):6342–88. DOI: 10.3390/molecules20046342Chiodelli P., Bugatti A., Urbinati C., Rusnati M. Heparin/heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use. Molecules. 2015;20(4):6342–88. DOI: 10.3390/molecules20046342Николаева М.Г., Григорьева Е.Е., Сердюк Г.В. Мамот А.П. Роль генетических детерминант тромбофилий в реализации репродуктивной функции женщин. Материалы Х юбилейного Всероссийского научного форума «Мать и дитя». 29.09.2009– 02.10.2009. Москва. С. 144–145.Nikolaeva M.G., Grigorieva E.E., Serdyuk G.V. Mamot A.P.The role of genetic determinants of thrombophilias in the realization of women’s reproductive function. Materials of the X Anniversary All-Russian Scientifi c Forum “Mother and Child” 29.09.2009–02.10.2009, Moscow. pp. 144–145. (In Russian)].Агаркова Т.А., Трифонова Е.А., Габитова Н.А. и др. Анализ генетических маркеров наследственной тромбофилии и эндотелиальной дисфункции при осложненном течении беременности. Материалы XI юбилейного Всероссийского научного форума «Мать и дитя». 28.09.2009–01.10.2010, Москва. С. 6–7.Agarkova T.A., Trifonova E.A., Gabitova N.A. et al. Analysis of genetic markers of hereditary thrombophilia and endothelial dysfunction in complicated pregnancy. pp. 6–7. Materials of the XI Anniversary All-Russian Scientifi c Forum “Mother and Child” 28.09.2009–01.10.2010, Moscow. (In Russian)].Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Morin F, Demers C, Kahn S R, Magee L A, Rodger M. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. Randomized Controlled Trial J. Thromb. Haemost. 2009;7(1):58–64. DOI: 10.1111/j.1538-7836.2008.03230.xRey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Morin F, Demers C, Kahn S R, Magee L A, Rodger M. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. Randomized Controlled Trial J. Thromb. Haemost. 2009;7(1):58–64. DOI: 10.1111/j.1538-7836.2008.03230.xHuang J., Chen X., Xing H., Chen L., Xie Z., He S.et al. Aspirin and heparin for the prevention of pre-eclampsia: protocol for a systematic review and network meta-analysis. BMJ Open. 2019;9(2):e026920. DOI: 10.1136/bmjopen-2018-026920Huang J., Chen X., Xing H., Chen L., Xie Z., He S.et al. Aspirin and heparin for the prevention of pre-eclampsia: protocol for a systematic review and network meta-analysis. BMJ Open. 2019;9(2):e026920. DOI: 10.1136/bmjopen-2018-026920Ed. J. Hirsh. Venous thromboembolism, trombophilia and pregnancy, pp 133-139 in Guidelines for Antithrombotic Therapy. 8th edition, 2008.Ed. J. Hirsh. Venous thromboembolism, trombophilia and pregnancy, pp 133-139 in Guidelines for Antithrombotic Therapy. 8th edition, 2008.Dias A.T.B., Modesto T.B., de Oliveira S.A. Eff ectiveness of the use of Low Molecular Heparin in patients with repetition abortion history: Systematic review and meta-analysis. JBRA Assist. Reprod. 2021;25(1):10–27.DOI: 10.5935/1518-0557.20200042Dias A.T.B., Modesto T.B., de Oliveira S.A. Eff ectiveness of the use of Low Molecular Heparin in patients with repetition abortion history: Systematic review and meta-analysis. JBRA Assist. Reprod. 2021;25(1):10–27.DOI: 10.5935/1518-0557.20200042Skeith L. Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation. Hematology Am. Soc. Hematol. Educ. Program. 2021; 2021(1):559–569. DOI: 10.1182/hematology.2021000291Skeith L. Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation. Hematology Am. Soc. Hematol. Educ. Program. 2021; 2021(1):559–569. DOI: 10.1182/hematology.2021000291Timp J. F., Braekkan S. K., Lijfering W. M., van Hylckama Vlieg A., Rosendaal F. R., le Cessie S., Cannegieter S.C., Rahimi K. Prediction of recurrent venous thrombosis in all patients with a fi rst venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP). PLoS Med. 2019;16(10):e1002883. DOI: 10.1371/journal.pmed.1002883Timp J. F., Braekkan S. K., Lijfering W. M., van Hylckama Vlieg A., Rosendaal F. R., le Cessie S., Cannegieter S.C., Rahimi K. Prediction of recurrent venous thrombosis in all patients with a fi rst venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP). PLoS Med. 2019;16(10):e1002883. DOI: 10.1371/journal.pmed.1002883Sahoo D.R., Dorairajan G., Palanivel C. Risk stratifi cation for venous thrombosis in post-partum women in a tertiary care setup in south India. Indian J. Med. Res. 2020;152(5):523–526. DOI: 10.4103/ijmr.IJMR_1564_18Sahoo D.R., Dorairajan G., Palanivel C. Risk stratifi cation for venous thrombosis in post-partum women in a tertiary care setup in south India. Indian J. Med. Res. 2020;152(5):523–526. DOI: 10.4103/ijmr.IJMR_1564_18Posch F., Thaler J., Zlabinger G-J., Königsbrügge O., Koder S., Zielinski C., Pabinger I., Ay C. Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study (CATS). Clin. Cancer Res. 2016;22(1):200-6. DOI: 10.1158/1078-0432.CCR-14-3358Posch F., Thaler J., Zlabinger G-J., Königsbrügge O., Koder S., Zielinski C., Pabinger I., Ay C. Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study (CATS). Clin. Cancer Res. 2016;22(1):200-6. DOI: 10.1158/1078-0432.CCR-14-3358Chaturvedi S., Braunstein E.M., Yuan X., Yu J., Alexander A., Chen H. et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020;135(4):239–25. 1DOI: 10.1182/blood.2019003863Chaturvedi S., Braunstein E.M., Yuan X., Yu J., Alexander A., Chen H. et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020;135(4):239–25. 1DOI: 10.1182/blood.2019003863Memtsas V.P., Arachchillage D.R. J., Gorog D.A., Muszbek L. Role, laboratory assessment and clinical relevance of fi brin, factor XIII and endogenous fi brinolysis in arterial and venous thrombosis. Int. J. Mol. Sci. 2021;22(3):1472. DOI: 10.3390/ijms22031472Memtsas V.P., Arachchillage D.R. J., Gorog D.A., Muszbek L. Role, laboratory assessment and clinical relevance of fi brin, factor XIII and endogenous fi brinolysis in arterial and venous thrombosis. Int. J. Mol. Sci. 2021;22(3):1472. DOI: 10.3390/ijms22031472

The authors declare that there are no conflicts of interest present.